Anaptysbio, Inc 8-K, filed May 21, 2026
Anaptysbio, Inc (ANAB)
About this 8-K
Anaptysbio, Inc filed this 8-K on May 21, 2026, reporting on events of May 18, 2026.
Items reported
- Item 5.03: Charter or bylaw amendment, or fiscal year change
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June 30. The Company’s next fiscal year will begin on July 1, 2026. The Company plans to file all required periodic reports under Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including a transition report on Form 10-KT for the six-month transition period of January 1, 2026 through June 30, 2026. The Company then will file quarterly reports based on the new fiscal year beginning with the quarter ending September 30, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ANAPTYSBIO, INC. |
|
|
|
|
Date: |
May 21, 2026 |
By: |
/s/ Christopher M. Murphy |
|
|
|
Name: Christopher M. Murphy |